
RAPT Stock Forecast & Price Target
RAPT Analyst Ratings
Bulls say
RAPT Therapeutics is well-positioned for future growth due to its innovative pipeline, particularly the RPT904 and JYB1904 programs, which could showcase differentiated efficacy in 2025, enhancing market interest. The company's RPT904, featuring a commercially validated mechanism of action with improved pharmacokinetics and half-life, represents a significant and de-risked opportunity in the immunologic and asthmatic markets. Additionally, the recent acquisition of Verona Pharma by Merck highlights the increasing value and focus within the pharmaceutical sector on immunology and inflammation therapeutics, potentially benefiting RAPT's strategic positioning.
Bears say
RAPT Therapeutics faces significant risks that contribute to a negative outlook, including the potential for safety signals to emerge from clinical or preclinical programs, which could adversely affect investor confidence. Additionally, the company may encounter challenges regarding the efficacy of its clinical programs, particularly if studies do not achieve the anticipated statistical significance, further complicating its development path. The company's financial health is also a concern, as it requires substantial financing estimated at approximately $1.1 billion through 2040, alongside a limited cash runway projected only until 2027.
This aggregate rating is based on analysts' research of Rapt Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPT Analyst Forecast & Price Prediction
Start investing in RAPT
Order type
Buy in
Order amount
Est. shares
0 shares